MOTE Therapeutics任命MaryJane Rafii为首席投资与商务官，以推动RNA递送平台的全球增长-动脉网

MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform

CISION 等信源发布 2025-07-03 18:07



可切换为仅中文







BOSTON

波士顿

，

July 3, 2025

2025年7月3日

/PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of

/PRNewswire/ -- 专注于开发靶向RNA递送解决方案的种子阶段生物技术公司MOTE Therapeutics（简称MOTE）宣布任命

MaryJane Rafii

玛丽·简·拉菲

, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZE platform, a modular LNP technology designed for extrahepatic delivery of circular RNA (circRNA) and other complex payloads.

，博士，工商管理硕士，担任首席投资和商务官。此举正值MOTE加速开发其MOBILIZE平台之际，该平台是一种模块化的LNP技术，旨在实现环状RNA（circRNA）和其他复杂载荷的肝外递送。

Dr. Rafii, a seasoned BD and capital strategist with over 15 years of global experience, will lead fundraising and partnership strategy as the company advances toward IND-enabling milestones. Her experience spans M&A, licensing, and fundraising across the U.S.,

拉菲博士是一位拥有超过15年全球经验的资深商务拓展和资本战略家，她将带领公司推进至新药临床试验申请（IND）关键节点时主导募资与合作战略。她的经验涵盖并购、授权及在美国等地的募资。

Europe

欧洲

，

Asia

亚洲

, and the UAE.

，以及阿联酋。

'MaryJane brings a strong track record of scaling biotech platforms through smart capital and strategic alliances,' said Roc Cui, Chairman of Fapon and Co-Founder of MOTE. 'She's joining at a pivotal time in our trajectory.'

“玛丽·简通过明智的资本运作和战略联盟，拥有扩展生物技术平台的卓越记录，”Fapon董事长、MOTE联合创始人崔洛克表示。“她在一个关键时期加入了我们的发展轨道。”

MOTE's Pitch: Functional, precise RNA delivery without the covalent complexity

MOTE的推介：功能性、精确的RNA递送，无需共价复杂性

Founded by Fapon Group and Dr. Wesselhoeft (Orna Therapeutics), MOTE is taking aim at one of RNA's most persistent challenges: cell-specific delivery beyond the liver. MOBILIZE LNPs use a bifunctional binder system—no chemical conjugation required—to enable rapid, mix-and-go assembly of targeted nanoparticles..

MOTE由Fapon集团和Wesselhoeft博士（Orna Therapeutics）创立，致力于解决RNA领域一个长期存在的难题：肝脏以外的细胞特异性递送。MOBILIZE LNPs采用双功能结合系统——无需化学偶联——即可实现靶向纳米颗粒的快速、即混即用组装。

Recent preclinical highlights include:

最近的临床前亮点包括：

80% reduction in liver uptake (enabling extrahepatic targeting)

肝脏摄取减少80%（实现肝外靶向）

~30% CAR+ CD8+ T-cell generation from a single low dose in NHP

在NHP中，单次低剂量下产生约30%的CAR+ CD8+ T细胞

B-cell depletion via in vivo CAR-T in NHPs

通过体内CAR-T实现NHPs中B细胞的清除

BBB-crossing delivery in CNS murine models

中枢神经系统小鼠模型中的BBB穿越递送

What's next?

接下来是什么？

MOTE is raising >

MOTE 正在提升 >

$40M

4000万美元

in Series A funding to support IND-enabling work for in vivo CAR-T programs in autoimmunity and hematologic cancers, with IITs (Investigator Initiated Trial) planned in the second half of 2025 in

A轮融资，以支持自身免疫和血液癌症的体内CAR-T项目的IND促成工作，并计划在2025年下半年进行IIT（研究者发起的试验）。

China

中国

. The pipeline also includes programs in HSPC disorders and neurodegeneration.

该管道还包括HSPC疾病和神经退行性疾病的项目。

'This is a delivery platform built to scale, with real data and broad applicability,' Rafii said. 'We're inviting partners to join us in pushing the boundaries of RNA medicine.'

“这是一个为规模化而构建的递送平台，具有真实的数据和广泛的适用性，”拉菲说。“我们邀请合作伙伴加入我们，共同推动RNA医学的边界。”

About MOTE Therapeutics

关于MOTE Therapeutics

MOTE Therapeutics (referred as MOTE) is a next-generation RNA therapeutics company focused on solving one of the most fundamental bottlenecks in nucleic acid medicine: delivering RNA payloads—particularly circular RNA (circRNA)—to cells and tissues outside the liver. The company's proprietary MOBILIZE platform is a modular, scalable, and chemistry-free system for functionalizing LNPs with cell-targeting specificity.

MOTE Therapeutics（简称 MOTE）是一家下一代 RNA 治疗公司，专注于解决核酸药物领域中最基本的瓶颈之一：将 RNA 载体——特别是环状 RNA（circRNA）——递送到肝脏以外的细胞和组织。该公司专有的 MOBILIZE 平台是一个模块化、可扩展且无需化学修饰的系统，能够为脂质纳米颗粒（LNP）赋予细胞靶向特异性。

It enables targeted circRNA delivery to previously inaccessible cell types—unlocking treatments for intractable diseases, such as systemic lupus erythematosus, multiple myeloma, and plasma cell leukemia, hematopoietic stem cell disorders and neurodegenerative diseases. Founded by Fapon Group and circular RNA pioneer Dr.

它能够将环状RNA靶向递送到以前无法到达的细胞类型——从而解锁对难治性疾病（如系统性红斑狼疮、多发性骨髓瘤、浆细胞白血病、造血干细胞疾病和神经退行性疾病）的治疗。该公司由华大集团和环状RNA先驱Dr.创立。

。

Alex Wesselhoeft

亚历克斯·韦塞尔霍夫特

, MOTE combines cutting-edge delivery science with a global footprint spanning the U.S. and

，MOTE 将尖端的递送科学与遍布美国和全球的业务相结合

China

中国

。

About Fapon

关于Fapon

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics.

菲鹏生物是一家全球领先的生命科学企业，致力于为诊断、生物制药和生物治疗提供整合解决方案和服务。公司通过整合原料、试剂及创新的开放仪器平台的一站式解决方案，已成为体外诊断领域的领先供应商。

Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in over 70 countries and regions, serving more than 2,500 business partners worldwide..

菲鹏生物在治疗技术和人工智能算法平台方面拥有先进的创新技术，并通过数据洞察助力构建更美好、更健康的世界。依托其强大的全球研发、制造、销售和服务网络，菲鹏生物的产品已覆盖超过70个国家和地区，为全球2500多家业务合作伙伴提供服务。

Investor Contacts:

投资者联系方式：

MaryJane Rafii

玛丽·简·拉菲

(

mjrafii@motetx.com

)

MOTE BD team (

MOTE BD团队 (

BD@motetx.com

)